Current experimental and early investigational agents for cardiac fibrosis: where are we at?

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Pathology

Background:

• Myocardial fibrosis (MF) is a pathological hallmark of heart disease, driven by diverse factors including inflammation, ischemia, hypertension, and aging.
• The development and characteristics of MF vary significantly, indicating multiple potential therapeutic targets.
• Existing heart failure treatments primarily address neurohormonal activation, with limited direct targeting of fibrosis and inflammation.

Purpose of the Study:

• To review current anti-fibrotic drugs used in clinical practice for myocardial fibrosis.
• To describe emerging therapeutic agents targeting specific fibrotic pathways.
• To synthesize evidence from preclinical and clinical studies on novel anti-fibrotic strategies.

Main Methods:

• Literature review of clinical trials and preclinical studies.
• Analysis of drug mechanisms targeting pro-fibrotic pathways.
• Examination of the role of inflammatory pathways and immune cells in cardiac fibrosis.

Main Results:

• While RAAS inhibitors show some anti-fibrotic effects, many current heart failure medications do not directly target inflammation or fibrosis.
• A gap exists between promising preclinical findings and limited clinical trials for novel anti-fibrotic agents.
• Emerging research highlights the complex roles of immune cells and cytokines in cardiac damage and repair.

Conclusions:

• Targeting specific inflammatory and fibrotic pathways holds promise for novel myocardial fibrosis treatments.
• Further clinical investigation is crucial to validate the efficacy of emerging anti-fibrotic therapies.
• A deeper understanding of the immune system's role in cardiac fibrosis is essential for developing effective interventions.